

# FAGRON N.V.

ISIN: BE0003874915 WKN: - Asset Class: **Stock**

## Company



2024/10/18 17:35:15

Price

**18.82**

EUR

Difference



0.43%(0.08)



## Contact Details

FAGRON NV Tel: +32-8-001-28-80  
-- Fax: +32-9-216-24-91  
Venecoweg 20A Web: <http://www.fagron.com>  
9810 Nazareth E-mail: -

## Company Profile

Fagron NV engages in the development, marketing, and distribution of healthcare products and services. It operates through the following segments: Essentials, Brands, and Compounding Services. The Essential segment focuses on supplying raw materials to community and hospital pharmacies for pharmaceutical compounding. The Brands segment is involved in developing and producing semi-finished products and vehicles, such as emulsions, powder mixtures, creams, and other excipients, as well as total concepts and equipment for pharmaceutical compounding. The Compounding Services segment offers community and hospital pharmacies with ready-to-use non-sterile compounded medicine in those countries where it is permitted. The company was founded in 1990 and is headquartered in Nazareth, Belgium.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	335,901,000		318,010,000		233,711,000	
Common stock capital		524,531,000		521,238,000		520,785,000
Fixed assets	671,053,000		653,000,000		566,710,000	
Equity capital of a company		467,626,000		410,518,000		325,466,000
Cash and cash equivalents	133,008,000		125,337,000		70,646,000	
Accrued liabilities		4,589,000		4,761,000		6,113,000
Other assets	-		-		-	
Current liabilities		175,258,000		171,009,000		145,062,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		364,070,000		389,483,000		329,893,000
Different income		-		-		-
Other liabilities		440,000		0		0
Total assets	1,006,954,000	1,006,954,000	971,010,000	971,010,000	800,421,000	800,421,000

## Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	3,282	3,035	2,846
Equity ratio	46.82%	42.89%	41.33%
Debt-equity ratio	113.56%	133.14%	141.95%

## Others

	2023	2022	2021
Tax Expense Rate	15.87%	20.17%	20.10%

## Income statement

	2023	2022	2021
<b>Turnover</b>	762,991,000	683,881,000	573,808,000
<b>Net income</b>	70,547,000	69,612,000	61,004,000
<b>EBIT</b>	102,100,000	100,256,000	88,099,000
<b>Operating income before taxes</b>	84,445,000	87,769,000	76,820,000
<b>Cash Flow</b>	107,379,000	97,551,000	64,650,000
<b>Net interest income</b>	-17,655,000	-12,487,000	-11,279,000
<b>Research and development expenses</b>	-	-	-
<b>Income taxes</b>	13,401,000	17,703,000	15,442,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	232,477	225,331	201,619

## Board of Directors

Koen Hoffman	Chairman of Supervisory Board
Ann Rita Desender	Member of Supervisory Board
Els Vandecandelaere	Member of Supervisory Board
Karin de Jong	Member of Supervisory Board
Klaus Röhrig	Member of Supervisory Board
Neeraj Sharma	Member of Supervisory Board
Robert J. W. ten Hoedt	Member of Supervisory Board

## Members of Management Board

Rafael Padilla	Chairman of Managing Board
Karin de Jong	Member of Executive Committee
Vera Bakker	Member of Executive Committee